Most people look at Lantern Pharma ($LTRN) and see a small biotech with a few oncology programs.
What they often miss is RADR.
RADR isn't a chatbot. It's an AI-driven oncology platform designed to identify which patients are most likely to respond to specific therapies by analyzing billions of data points across genomics, transcriptomics, drug response datasets, and clinical outcomes.
Instead of asking:
"Which drug fits this cancer?"
RADR asks:
"Which patients are most likely to benefit from this drug?"
That distinction matters.
LP-300 is a perfect example. Rather than treating all EGFR-mutated patients as one group, RADR identified the L858R subgroup as a potentially stronger responder population. Early clinical data appears to support that hypothesis.
If further data confirms these findings, RADR won't just be a research tool. It will have demonstrated the ability to uncover clinically meaningful patient populations that traditional approaches may overlook.
That's exactly the type of capability pharma companies are increasingly looking for.
And with a market cap around $50M, I believe the market is still largely valuing Lantern as a small biotech, not as a company with a potentially scalable AI-driven precision oncology platform.
Just my opinion, but RADR may ultimately prove to be worth more than any single drug in the pipeline.